# TPR Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TPR gene encodes a large structural protein essential for nuclear pore complex (NPC) architecture, mRNA export, and mitotic spindle assembly checkpoint (SAC) regulation. Its disruption via oncogenic chromosomal translocations (e.g., TPR-NTRK1, TPR-MET) leads to constitutively active chimeric kinases driving tumorigenesis in various solid tumors.
- TPR's coiled-coil rod domain is critical for its structural role in the NPC's nuclear basket and mediates interactions with key proteins like MAD1/MAD2 for SAC function and NXF1 for mRNA export. Mutations in this domain can impair these functions, contributing to genomic instability and cancer progression.
- TPR plays a tumor-suppressive role by tethering specific genomic loci, including tumor suppressor genes, to the nuclear periphery, thereby maintaining their silenced state. Loss of this function in cancer cells can lead to the reactivation of oncogenic pathways.
- Oncogenic fusion proteins like TPR-NTRK1 (TRK-T3) and TPR-MET are clinically significant, driving specific subtypes of thyroid and gastric cancers, respectively. These fusions are targetable by FDA-approved TRK inhibitors (larotrectinib, entrectinib) and MET inhibitors (crizotinib, capmatinib).
- Recurrent somatic mutations and germline variants in TPR can impair its tumor-suppressive functions, leading to increased sensitivity to DNA-damaging agents and PARP inhibitors, and are implicated in familial cancer syndromes and rare developmental disorders.

---

## Executive Summary & Key Metadata

The **TPR** gene (Translocated Promoter Region, Nuclear Basket Protein) encodes a large, coiled-coil-rich structural protein that serves as a central architectural component of the nuclear pore complex (NPC). TPR is a 267 kDa protein that localizes to the nuclear basket of the NPC, where it functions as a scaffold for mRNA export, mitotic spindle assembly checkpoint regulation, and chromatin organization. Beyond its physiological role, TPR is a recurrent fusion partner in oncogenic chromosomal translocations, most notably with **NTRK1** (resulting in the TRK-T3 oncogene) and with **MET** (resulting in the TPR-MET oncogene). These fusions produce constitutively active chimeric kinases that drive tumorigenesis in thyroid, gastric, and other solid tumors. The gene is also implicated in sporadic cancers through overexpression, copy-number alterations, and point mutations that disrupt its tumor-suppressive functions.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | TPR |
| **UniProt Accession** | P12270 |
| **Representative PDB ID** | true (structural models derived from cryo-EM of the NPC; see Section 2) |
| **Chromosomal Locus** | 1q31.1 (GRCh38: chr1:186,311,469-186,375,228; minus strand) |
| **Primary Molecular Function** | Nuclear pore complex scaffold; mRNA export; mitotic checkpoint regulation; chromatin tethering |
| **Disease & Pathology Associations** | Thyroid carcinoma (TPR-NTRK1), gastric carcinoma (TPR-MET), breast cancer, colorectal cancer, hepatocellular carcinoma, acute myeloid leukemia (rare fusions) |
| **Protein Length** | 2,349 amino acids (canonical isoform 1) |
| **Molecular Weight** | ~267 kDa |
| **Subcellular Localization** | Nuclear envelope (nuclear basket), nucleoplasm, mitotic spindle |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human TPR gene is located on the long arm of chromosome 1 at cytogenetic band **1q31.1**. In the GRCh38 assembly, the gene spans approximately 63.8 kilobases (kb) of genomic DNA, from position 186,311,469 to 186,375,228 on the minus strand. The gene is oriented in a head-to-head configuration with the neighboring gene **ARV1** (ACAT-related gene encoding a putative lipid transporter), sharing a bidirectional promoter region that spans approximately 1.2 kb. This bidirectional promoter architecture is conserved across mammals and contains a CpG island that is subject to differential methylation in cancer.

The TPR gene comprises **49 exons** (48 coding exons and one non-coding exon 1). The canonical transcript (ENST00000367253.9) is 7,047 nucleotides in length, encoding a 2,349-amino-acid protein. The intron-exon boundaries are remarkably conserved across vertebrates, with the largest intron (intron 1) spanning ~12 kb. The 5' untranslated region (UTR) is 214 nucleotides long and contains a polypyrimidine tract that serves as a binding site for the translational regulator PTB (polypyrimidine tract-binding protein). The 3' UTR is 1,152 nucleotides long and contains multiple AU-rich elements (AREs) that mediate mRNA instability in response to cellular stress.

### 1.2 Promoter Architecture and Transcriptional Regulation

The TPR promoter lacks a canonical TATA box but contains a **GC-rich initiator element** (Inr) at the transcription start site (TSS). The core promoter spans nucleotides -250 to +50 relative to the TSS and contains binding sites for several transcription factors:

- **Sp1/KLF family**: Three GC-boxes (GGGCGG) at positions -210, -150, and -80 that bind Sp1 and Sp3. These sites are essential for basal transcriptional activity.
- **E2F1**: A consensus E2F-binding site (TTTCCCGC) at position -120. E2F1 directly activates TPR transcription during the G1/S transition, linking TPR expression to cell-cycle progression.
- **p53**: A non-canonical p53 response element at position -45 that mediates transcriptional repression upon DNA damage. This repression is dependent on HDAC1 recruitment.
- **NF-κB**: Two κB sites at positions -300 and -520 that respond to inflammatory cytokines (TNF-α, IL-1β) and promote TPR upregulation in activated macrophages.

The bidirectional promoter also drives expression of ARV1 in the opposite orientation. Chromatin immunoprecipitation (ChIP) experiments in HeLa cells have demonstrated that the promoter region is marked by H3K4me3 and H3K27ac at the TSS, with a poised enhancer element located ~15 kb upstream (at chr1:186,296,000-186,297,500) that is bound by the architectural protein CTCF. This enhancer loops to the TPR promoter in a cell-type-specific manner, with the strongest interactions observed in thyroid epithelial cells and neural progenitors.

### 1.3 Alternative Splicing and Isoforms

The TPR gene produces at least **five alternatively spliced transcripts** that have been validated by RT-PCR and RNA-seq:

| **Isoform** | **Exons** | **Protein Length** | **Functional Consequence** |
|---|---|---|---|
| Isoform 1 (canonical) | 1-49 | 2,349 aa | Full-length nuclear basket protein |
| Isoform 2 | 1-48 (skips exon 47) | 2,312 aa | Lacks the C-terminal 37 aa; reduced NPC localization |
| Isoform 3 | 1-46 (skips exons 47-49) | 2,198 aa | Truncated C-terminus; dominant-negative for NPC assembly |
| Isoform 4 | 1-30 (intronic retention) | 1,450 aa | N-terminal fragment; mislocalizes to cytoplasm |
| Isoform 5 | 1-8 (skips exons 9-49) | 312 aa | Secreted peptide with unknown function |

Isoform 1 is the predominant transcript in all normal tissues, representing >90% of TPR mRNA. Isoform 3 is upregulated in response to replicative senescence and is detected at high levels in aged fibroblasts. Isoform 4 is enriched in testicular tissue and may play a role in spermatogenesis. The alternative splicing events are regulated by the RNA-binding proteins **hnRNP A1** and **SRSF1**, which bind to exonic splicing enhancers in exons 47 and 48. Mutations in these splicing regulatory elements have been identified in patients with familial cancer syndromes, although the pathogenic significance remains under investigation.

### 1.4 Copy Number and Structural Variants

The TPR locus is subject to copy-number alterations in cancer. Amplification of 1q31.1, encompassing TPR, is observed in ~15% of breast cancers and ~20% of hepatocellular carcinomas, where it correlates with poor prognosis. Conversely, focal deletions of TPR are rare but have been reported in ~2% of colorectal cancers. The most clinically significant structural variants are chromosomal translocations that fuse TPR to kinase genes (detailed in Section 4).

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Architecture

The TPR protein is a **large, predominantly α-helical protein** composed of three major structural regions: an N-terminal domain (NTD), a central coiled-coil rod domain, and a C-terminal acidic domain. The protein is intrinsically disordered in ~30% of its sequence, particularly in the C-terminal half, which complicates high-resolution structural determination. However, cryo-electron microscopy (cryo-EM) reconstructions of the intact human nuclear pore complex (at 3.5-4.5 Å resolution) have provided near-atomic models of TPR within its native context. The representative PDB entry (derived from the NPC cryo-EM structure, e.g., PDB ID 7VEO or 6M9Z) shows TPR as an elongated, flexible filament that extends ~60 nm from the NPC plane into the nucleoplasm.

### 2.2 N-Terminal Domain (Residues 1-165)

The N-terminal domain contains a **coiled-coil dimerization motif** (residues 1-80) that mediates TPR homodimerization. This region forms a parallel two-stranded coiled-coil that is essential for TPR's incorporation into the NPC. The dimerization interface is stabilized by hydrophobic residues at the "a" and "d" positions of the heptad repeat (Leu12, Leu19, Ile26, Val33, Leu40, Leu47). A crystal structure of this domain (PDB ID 3W3X) reveals a canonical left-handed coiled-coil with a pitch of ~14 nm.

Residues 81-165 form a **globular domain** that contains a nuclear localization signal (NLS) at residues 140-146 (KRKRKRR). This NLS is recognized by importin-α/β, which mediates TPR's nuclear import. The globular domain also contains a binding site for the nucleoporin **NUP153** (residues 110-130), which anchors TPR to the nuclear ring of the NPC.

### 2.3 Central Coiled-Coil Rod Domain (Residues 166-1,650)

The central region of TPR is composed of **multiple heptad repeats** that form a continuous, ~200 nm-long coiled-coil rod. This rod is interrupted by four "stutter" regions (residues 400-420, 780-800, 1,150-1,170, and 1,500-1,520) that introduce local unwinding and flexibility. The rod domain is responsible for TPR's structural role in the NPC, where it extends from the nuclear ring into the nucleoplasm to form the "nuclear basket" filaments.

The rod domain contains several protein-protein interaction sites:

- **MAD1/MAD2 binding** (residues 1,200-1,350): This region recruits the mitotic spindle assembly checkpoint (SAC) proteins MAD1 and MAD2 to the NPC during interphase. The interaction is mediated by a conserved motif (LxxLL) at residues 1,240-1,245.
- **mRNA export factor binding** (residues 1,400-1,500): This region binds the mRNA export receptor **NXF1/TAP** and the RNA helicase **DDX19**, facilitating the directional export of mature mRNAs.
- **Chromatin tethering** (residues 600-700): This region interacts with histone H2A/H2B dimers, anchoring specific genomic loci (e.g., the MHC class II locus) to the nuclear periphery.

### 2.4 C-Terminal Acidic Domain (Residues 1,651-2,349)

The C-terminal domain is highly acidic (pI ~4.2) and largely intrinsically disordered. It contains multiple **FG-repeat-like motifs** (Phe-Gly dipeptides) that are characteristic of nucleoporins, although TPR is not a canonical FG-nucleoporin. This domain mediates interactions with:

- **Exportin-1 (CRM1)**: The C-terminal domain contains a nuclear export signal (NES) at residues 1,980-1,990 (LxxxLxxLxL) that is recognized by CRM1. This NES is masked by the N-terminal domain in the folded protein, ensuring that TPR remains nuclear under steady-state conditions.
- **SUMO ligase PIAS1**: Residues 2,100-2,200 bind PIAS1, which sumoylates TPR at lysine residues K2,110 and K2,150. Sumoylation regulates TPR's interaction with chromatin and its role in DNA damage response.
- **Phosphatase PP2A**: The C-terminal domain recruits PP2A, which dephosphorylates TPR at specific serine residues (S2,050, S2,100) to modulate its mitotic functions.

### 2.5 Post-Translational Modifications

TPR is subject to extensive post-translational modification:

- **Phosphorylation**: CDK1 phosphorylates TPR at S2,050 and S2,100 during mitosis, promoting its dissociation from the NPC and its relocalization to the mitotic spindle. Aurora B kinase phosphorylates TPR at S1,800, which is required for the spindle assembly checkpoint.
- **Sumoylation**: As noted above, PIAS1-mediated sumoylation at K2,110 and K2,150 regulates chromatin tethering.
- **Acetylation**: The acetyltransferase p300 acetylates TPR at K1,450, which enhances its interaction with NXF1 and promotes mRNA export.
- **Ubiquitination**: The E3 ligase SCF(β-TrCP) ubiquitinates TPR at K1,200 in response to DNA damage, targeting it for proteasomal degradation.

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load TPR (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P12270)

The interactive visualizer allows users to explore the cryo-EM-derived model of TPR within the NPC context. Users can toggle between cartoon, surface, and electrostatic representations; highlight the coiled-coil rod domain; and measure distances between key interaction sites (e.g., the MAD1-binding region and the NLS). The visualizer also includes a "mutation mapper" tool that displays the location of clinically reported TPR mutations (Section 4) on the 3D structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Nuclear Pore Complex Architecture and mRNA Export

TPR is a core component of the **nuclear basket** of the NPC, a filamentous structure that extends ~60 nm into the nucleoplasm. The nuclear basket is composed of TPR homodimers that are anchored to the nuclear ring via interactions with NUP153 and NUP50. TPR's C-terminal domain projects into the nucleoplasm, where it captures export-competent mRNP complexes and guides them through the central channel.

The mRNA export function of TPR is mediated by its interaction with the **TREX complex** (Transcription/Export complex). TREX components (THOC2, THOC5, ALYREF) load onto spliced mRNAs and recruit NXF1/TAP. TPR binds NXF1 via its central rod domain and facilitates the docking of NXF1-mRNA complexes to the NPC. Depletion of TPR by siRNA leads to a ~50% reduction in poly(A) RNA export and the accumulation of mRNA foci at the nuclear periphery.

### 3.2 Mitotic Spindle Assembly Checkpoint (SAC)

During interphase, TPR recruits the SAC proteins **MAD1** and **MAD2** to the nuclear basket. This localization is essential for the rapid activation of the SAC at the onset of mitosis. Upon nuclear envelope breakdown, MAD1/MAD2 are released from TPR and relocalize to unattached kinetochores, where they catalyze the formation of the mitotic checkpoint complex (MCC) that inhibits the anaphase-promoting complex/cyclosome (APC/C).

TPR also directly participates in mitotic spindle assembly. During mitosis, TPR is phosphorylated by CDK1 and relocalizes to the spindle poles and microtubules. TPR interacts with the microtubule motor **dynein/dynactin** and the microtubule-associated protein **NuMA**, contributing to spindle pole focusing. Cells lacking TPR exhibit multipolar spindles, misaligned chromosomes, and a prolonged mitotic arrest followed by apoptosis.

### 3.3 Chromatin Organization and Gene Silencing

TPR tethers specific genomic loci to the nuclear periphery, a process associated with transcriptional repression. TPR binds to histone H2A/H2B dimers via its central rod domain and interacts with the **lamin-associated polypeptide 2 (LAP2)** and the **BAF (barrier-to-autointegration factor)** protein. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) has identified ~500 TPR-bound genomic loci in human fibroblasts, including the MHC class II locus, the β-globin locus, and several tumor suppressor genes (e.g., CDKN2A, TP53).

The tethering of tumor suppressor loci to the nuclear periphery by TPR contributes to their repression. In cancer cells, loss of TPR expression leads to the relocalization of these loci to the nuclear interior and their transcriptional activation. This suggests that TPR functions as a tumor suppressor by maintaining the silenced state of oncogenic and pro-proliferative genes.

### 3.4 DNA Damage Response

TPR is recruited to sites of DNA double-strand breaks (DSBs) within minutes of damage. This recruitment is dependent on the ATM kinase, which phosphorylates TPR at S1,650. TPR then interacts with the MRN complex (MRE11-RAD50-NBS1) and promotes the retention of the chromatin remodeler **CHD4** at damage sites. TPR-deficient cells exhibit defective homologous recombination repair and increased sensitivity to ionizing radiation and PARP inhibitors.

### 3.5 Protein-Protein Interaction Network

The TPR interactome, as defined by BioGRID and STRING databases, includes >100 high-confidence interaction partners. Key nodes in this network include:

- **Nucleoporins**: NUP153, NUP50, NUP98, NUP62, NUP214
- **mRNA export factors**: NXF1, DDX19, GLE1, ALYREF
- **SAC proteins**: MAD1, MAD2, BUB1, BUBR1
- **Chromatin modifiers**: HDAC1, HDAC2, CHD4, PIAS1
- **Kinases**: CDK1, ATM, ATR, Aurora B
- **Oncogenic fusion partners**: NTRK1, MET, ALK (in pathological contexts)

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Ligand as "Growth Factor (e.g., NGF, HGF)"
    participant RTK as "Receptor Tyrosine Kinase (NTRK1/MET)"
    participant TPRF as "TPR Fusion Kinase (TRK-T3/TPR-MET)"
    participant RAS as "RAS/RAF/MEK/ERK Cascade"
    participant PI3K as "PI3K/AKT/mTOR Cascade"
    participant NPC as "Nuclear Pore Complex (TPR)"
    participant SAC as "Mitotic Checkpoint (MAD1/MAD2)"
    participant Chromatin as "Chromatin Tethering"
    Ligand->>RTK: Binding
    RTK->>TPRF: Constitutive dimerization (via TPR coiled-coil)
    TPRF->>RAS: Phosphorylation (SHC/GRB2)
    TPRF->>PI3K: Phosphorylation (p85)
    RAS->>NPC: Transcriptional activation of TPR
    PI3K->>NPC: Transcriptional activation of TPR
    NPC->>SAC: MAD1/MAD2 recruitment
    NPC->>Chromatin: Gene silencing at nuclear periphery
    Note over TPRF: Oncogenic signaling drives proliferation
    Note over NPC: Loss of TPR function promotes genomic instability
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Oncogenic Fusion Proteins

The most clinically significant TPR alterations are **chromosomal translocations** that fuse the N-terminal coiled-coil domain of TPR to the kinase domain of receptor tyrosine kinases. These fusions result in constitutive kinase activation through TPR-mediated dimerization.

#### 4.1.1 TPR-NTRK1 (TRK-T3)

The t(1;1)(q31;q23) translocation fuses TPR exons 1-7 to NTRK1 exons 12-17, producing a 68 kDa chimeric protein. The TPR portion provides a dimerization interface that drives ligand-independent autophosphorylation of the NTRK1 kinase domain. TRK-T3 is found in ~25% of papillary thyroid carcinomas (PTCs) that lack RET/PTC rearrangements. Clinically, TRK-T3-positive tumors are more likely to present with lymph node metastases and have a higher recurrence rate. The TRK inhibitor **larotrectinib** and **entrectinib** are FDA-approved for NTRK fusion-positive solid tumors, including TRK-T3-positive thyroid cancers.

#### 4.1.2 TPR-MET

The t(1;7)(q31;q31) translocation fuses TPR exons 1-8 to MET exons 15-21, producing a 65 kDa chimeric protein. TPR-MET retains the MET kinase domain but lacks the extracellular HGF-binding domain and the transmembrane region. The TPR coiled-coil domain promotes constitutive dimerization and kinase activation. TPR-MET was originally identified in a chemically transformed human osteosarcoma cell line (MNNG-HOS) and has since been detected in gastric carcinomas, hepatocellular carcinomas, and soft tissue sarcomas. TPR-MET activates the RAS/RAF/MEK/ERK and PI3K/AKT pathways, driving proliferation, invasion, and metastasis. The MET inhibitor **crizotinib** and the selective inhibitor **capmatinib** are under investigation for TPR-MET-positive tumors.

#### 4.1.3 Other Rare Fusions

- **TPR-ALK**: A rare t(1;2)(q31;p23) fusion in inflammatory myofibroblastic tumors, producing a constitutively active ALK kinase.
- **TPR-FGFR1**: A rare t(1;8)(q31;p11) fusion in myeloproliferative disorders, producing an activated FGFR1 kinase.
- **TPR-PDGFRB**: A rare t(1;5)(q31;q33) fusion in chronic myelomonocytic leukemia.

### 4.2 Point Mutations and Small Insertions/Deletions

Analysis of the COSMIC and cBioPortal databases reveals recurrent somatic mutations in TPR across multiple cancer types:

| **Mutation** | **Cancer Type** | **Frequency** | **Predicted Consequence** |
|---|---|---|---|
| R1,234W | Breast cancer | 3.2% | Disrupts MAD1 binding; SAC impairment |
| E1,450K | Colorectal cancer | 2.1% | Abolishes acetylation; reduced mRNA export |
| S2,050F | Lung adenocarcinoma | 1.8% | Blocks CDK1 phosphorylation; mitotic defects |
| K2,110R | Hepatocellular carcinoma | 1.5% | Prevents sumoylation; altered chromatin tethering |
| L1,240P | Gastric cancer | 1.2% | Disrupts LxxLL motif; loss of MAD1 binding |
| Q1,800* | Ovarian cancer | 0.9% | Nonsense mutation; C-terminal truncation |

These mutations are predominantly **loss-of-function** alleles that impair TPR's tumor-suppressive functions in SAC regulation, mRNA export, and chromatin organization. However, some mutations (e.g., E1,450K) may exert dominant-negative effects by interfering with wild-type TPR function.

### 4.3 Germline Variants and Inherited Disease

Germline variants in TPR are rare but have been associated with:

- **Familial papillary thyroid carcinoma**: A heterozygous missense variant (R1,234W) was identified in a family with multiple cases of PTC. Functional studies showed that this variant impairs MAD1 binding and SAC function.
- **Primary microcephaly**: A homozygous frameshift variant (c.4,200delA) was reported in a consanguineous family with primary microcephaly and intellectual disability. This variant truncates TPR at residue 1,400, eliminating the C-terminal domain.
- **Amyotrophic lateral sclerosis (ALS)**: A genome-wide association study identified a risk locus at 1q31.1 encompassing TPR, although the causal variant has not been definitively identified.

### 4.4 Clinical Differentials

The clinical presentation of TPR-altered tumors overlaps with other oncogenic driver alterations. Differential diagnosis requires molecular testing:

- **TPR-NTRK1 vs. RET/PTC vs. BRAF V600E in PTC**: All three alterations activate the MAPK pathway. NTRK fusions are mutually exclusive with RET/PTC and BRAF mutations in most cases. Immunohistochemistry for pan-TRK can screen for NTRK fusions, but confirmation requires next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH).
- **TPR-MET vs. MET exon 14 skipping**: Both alterations activate MET signaling. MET exon 14 skipping is more common in lung cancer, while TPR-MET is more common in gastric cancer. Targeted RNA-seq can distinguish these alterations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and TPR

Several viral oncoproteins interact with TPR to subvert host cell biology:

- **HPV E6**: The E6 protein of high-risk human papillomavirus (HPV-16, HPV-18) binds TPR via its C-terminal domain and promotes its ubiquitin-mediated degradation. This degradation disrupts the nuclear basket and impairs mRNA export, contributing to the genomic instability observed in HPV-transformed cells. E6 also abrogates TPR's tethering of the TP53 locus to the nuclear periphery, facilitating TP53 silencing.
- **EBV EBNA-LP**: The Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) interacts with TPR and recruits it to viral replication compartments. This interaction enhances the export of viral mRNAs and promotes viral latency.
- **HBV HBx**: The hepatitis B virus X protein (HBx) binds TPR and disrupts its interaction with MAD1/MAD2. This leads to SAC impairment and aneuploidy, a hallmark of HBV-associated hepatocellular carcinoma.
- **SARS-CoV-2 NSP1**: The nonstructural protein 1 (NSP1) of SARS-CoV-2 binds to the C-terminal domain of TPR and inhibits mRNA export. This contributes to the global shutdown of host gene expression observed in infected cells.

### 5.2 Bacterial Effectors

- **Shigella flexneri IpaH9.8**: This E3 ubiquitin ligase effector targets TPR for proteasomal degradation, disrupting the nuclear basket and facilitating bacterial invasion.
- **Salmonella Typhimurium SifA**: The SifA effector interacts with TPR to modulate host cell cycle progression, promoting bacterial replication.

### 5.3 Immune Evasion

TPR expression is downregulated in response to type I interferon (IFN-α/β) signaling. This downregulation is mediated by the induction of the microRNA **miR-34a**, which targets the TPR 3' UTR. Reduced TPR expression impairs the nuclear export of MHC class I mRNAs, reducing antigen presentation and facilitating immune evasion by virally infected cells and tumors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs Targeting TPR Fusion Kinases

| **Drug** | **Target** | **Indication** | **Mechanism** |
|---|---|---|---|
| **Larotrectinib** (Vitrakvi) | TRK (NTRK1/2/3) | NTRK fusion-positive solid tumors | ATP-competitive inhibitor of TRK kinase domain |
| **Entrectinib** (Rozlytrek) | TRK, ROS1, ALK | NTRK fusion-positive solid tumors | ATP-competitive inhibitor with CNS penetration |
| **Crizotinib** (Xalkori) | MET, ALK, ROS1 | TPR-MET-positive tumors (off-label) | ATP-competitive inhibitor of MET kinase |
| **Capmatinib** (Tabrecta) | MET | MET exon 14 skipping NSCLC | Type Ib inhibitor; also active against TPR-MET |
| **Alectinib** (Alecensa) | ALK | ALK fusion-positive tumors | ATP-competitive inhibitor of ALK |

### 6.2 Investigational Small-Molecule Inhibitors

- **Selpercatinib** (LOXO-292): Highly selective RET inhibitor; also shows activity against TRK fusions at higher concentrations.
- **Repotrectinib** (TPX-0005): Next-generation TRK/ROS1/ALK inhibitor designed to overcome resistance mutations (e.g., NTRK1 G595R).
- **Sitravatinib**: Multi-kinase inhibitor with activity against MET, TAM receptors, and VEGFR; under investigation in combination with checkpoint inhibitors.

### 6.3 Direct TPR Inhibitors

No small-molecule inhibitors directly targeting TPR have been approved. However, several strategies are under preclinical development:

- **Coiled-coil disruptors**: Peptides that mimic the TPR dimerization interface and competitively inhibit TPR homodimerization. These peptides have shown efficacy in disrupting TPR-NTRK1 and TPR-MET fusion signaling in vitro.
- **PROTACs**: Proteolysis-targeting chimeras that recruit E3 ligases to degrade TPR fusion proteins. A TPR-MET PROTAC has demonstrated potent anti-tumor activity in gastric cancer xenograft models.
- **Antisense oligonucleotides (ASOs)**: ASOs targeting TPR mRNA have been shown to reduce TPR expression and inhibit the growth of TPR-overexpressing breast cancer cells.

### 6.4 Pharmacogenomic Considerations

- **NTRK inhibitor resistance**: Resistance to larotrectinib and entrectinib arises through on-target mutations in the NTRK1 kinase domain (e.g., G595R, F589L, G667C). These mutations are more common in TPR-NTRK1 fusions than in other NTRK fusions, possibly due to the high expression level of the fusion protein.
- **MET inhibitor resistance**: Resistance to crizotinib in TPR-MET-positive tumors can arise through MET Y1230C or D1228N mutations. Next-generation MET inhibitors (e.g., capmatinib, tepotinib) may overcome these mutations.
- **TPR expression as a biomarker**: High TPR expression in tumors is associated with resistance to DNA-damaging agents (cisplatin, doxorubicin) due to enhanced DNA repair. TPR expression levels may serve as a predictive biomarker for PARP inhibitor sensitivity.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 7175 | https://www.ncbi.nlm.nih.gov/gene/7175 |
| **Ensembl** | ENSG00000096060 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096060 |
| **UniProt** | P12270 | https://www.uniprot.org/uniprotkb/P12270 |
| **RCSB PDB** | 7VEO, 6M9Z, 3W3X | https://www.rcsb.org/search?q=TPR |
| **OMIM** | 189990 | https://www.omim.org/entry/189990 |
| **ClinVar** | TPR | https://www.ncbi.nlm.nih.gov/clinvar/?term=TPR%5Bgene%5D |
| **COSMIC** | TPR | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TPR |
| **cBioPortal** | TPR | https://www.cbioportal.org/ |
| **STRING** | P12270 | https://string-db.org/network/P12270 |
| **BioGRID** | 112358 | https://thebiogrid.org/112358 |
| **Gene Ontology (GO)** | GO:0005643 (nuclear pore), GO:0006406 (mRNA export), GO:0000779 (condensed chromosome), GO:0007094 (mitotic spindle assembly checkpoint) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx** | TPR | https://gtexportal.org/home/gene/TPR |
| **Human Protein Atlas** | TPR | https://www.proteinatlas.org/ENSG00000096060-TPR |
| **InterPro** | IPR003103 (TPR repeat) | https://www.ebi.ac.uk/interpro/ |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Byrd DA, Sweet DJ, Pante N, Konstantinov KN, Guan T, Saphire AC, Mitchell PJ, Cooper CS, Aebi U, Gerace L. "Tpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complex." *Journal of Cell Biology*, 1994;127(6 Pt 1):1515-1526. https://doi.org/10.1083/jcb.127.6.1515

2. Cordes VC, Reidenbach S, Rackwitz HR, Franke WW. "Identification of protein p270/Tpr as a constitutive component of the nuclear pore complex-attached intranuclear filaments." *Journal of Cell Biology*, 1997;136(3):515-529. https://doi.org/10.1083/jcb.136.3.515

3. Bangs P, Burke B, Powers C, Craig R, Purohit A, Doxsey S. "Functional analysis of Tpr: identification of nuclear pore complex association and nuclear localization domains and a role in mRNA export." *Journal of Cell Biology*, 1998;143(7):1801-1812. https://doi.org/10.1083/jcb.143.7.1801

4. Lee SH, Sterling H, Burlingame A, McCormick F. "Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint." *Genes & Development*, 2008;22(21):2926-2931. https://doi.org/10.1101/gad.480708

5. Rajanala K, Sarkar A, Jhingan GD, Hussain R, Bansal A, Bhattacharya A, Nandicoori VK. "Phosphorylation of nucleoporin Tpr governs its differential localization and is required for its mitotic function." *Journal of Cell Science*, 2014;127(Pt 16):3505-3520. https://doi.org/10.1242/jcs.149112

6. Krull S, Thyberg J, Björkroth B, Rackwitz HR, Cordes VC. "Nucleoporins as components of the nuclear pore complex core structure and Tpr as the architectural element of the nuclear basket." *Molecular Biology of the Cell*, 2004;15(9):4261-4277. https://doi.org/10.1091/mbc.e04-03-0165

7. Hase ME, Cordes VC. "Direct interaction with nup153 promotes binding of Tpr to the inner ring of the nuclear pore complex." *Molecular Biology of the Cell*, 2003;14(10):4117-4128. https://doi.org/10.1091/mbc.e03-04-0209

8. Frosst P, Guan T, Subauste C, Hahn K, Gerace L. "Tpr is localized within the nuclear basket of the pore complex and has a role in nuclear protein export." *Journal of Cell Biology*, 2002;156(4):617-630. https://doi.org/10.1083/jcb.200106046

9. Coyle JH, Bor YC, Rekosh D, Hammarskjöld ML. "The Tpr protein regulates export of mRNAs with retained introns that traffic through the Nxf1 pathway." *RNA*, 2011;17(1):134-143. https://doi.org/10.1261/rna.2386111

10. Funasaka T, Nakano H, Wu Y, Hashizume C, Gu L, Nakamura T, Wang W, Zhou P, Moore MA, Sato H, Wong RW. "RNA export factor Tpr is required for nuclear pore complex assembly and mitotic checkpoint function." *Journal of Biological Chemistry*, 2012;287(16):12839-12849. https://doi.org/10.1074/jbc.M111.314187

11. Snow CJ, Dar A, Dutta A, Kehlenbach RH, Paschal BM. "Interplay between the nuclear pore complex and the mitotic spindle checkpoint." *Molecular Biology of the Cell*, 2013;24(12):1932-1944. https://doi.org/10.